 | Form 4 Filings | Insider Buys | Significant Buys | Penny Stocks Insider Buying | Insider Sales |
| Insider Buy Sell Ratios | Stock Options | Insider Trading Stock Screener | Insider Trading Graph View | Insider Watch |
Insider Trading - Keros Therapeutics Inc. (KROS)
| | "Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise" - Peter Lynch What is insider trading>> SPAC List: List of Special Purpose Acquisition Companies |
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2020-04-13 Purchase | 2020-04-13 5:12 pm | Keros Therapeutics Inc. | KROS | GORDON CARL L Director | 375,200 | $16 | $6,003,200 | 1,119,812 (Indirect) | View |
| 2020-04-13 Purchase | 2020-04-13 5:13 pm | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 437,499 | $16 | $6,999,984 | 149,262 (Indirect) | View |
| 2020-04-13 Purchase | 2020-04-13 5:15 pm | Keros Therapeutics Inc. | KROS | Lazarus Alon Director 10% Owner | 120,000 | $16 | $1,920,000 | 2,013,102 (Indirect Direct) | View |
| 2020-04-13 Purchase | 2020-04-13 5:16 pm | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 437,499 | $16 | $6,999,984 | 149,262 (Indirect) | View |
| 2020-04-13 Purchase | 2020-04-13 5:17 pm | Keros Therapeutics Inc. | KROS | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC Director | 375,200 | $16 | $6,003,200 | 1,119,812 (Indirect) | View |
| 2020-04-13 Purchase | 2020-04-13 5:18 pm | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 437,499 | $16 | $6,999,984 | 149,262 (Indirect) | View |
| 2020-04-13 Purchase | 2020-04-13 5:19 pm | Keros Therapeutics Inc. | KROS | Seehra Jasbir CEO | 20,000 | $16 | $320,000 | 243,856 (Direct) | View |
| 2020-04-13 Purchase | 2020-04-13 5:29 pm | Keros Therapeutics Inc. | KROS | Arkin Bio Ventures Limited Partnership Arkin Bio Venture Partners Ltd. Arkin Moshe 10% Owner | 120,000 | $16 | $1,920,000 | 2,013,102 (Direct) | View |
| 2020-11-17 Purchase | 2020-11-19 4:38 pm | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 60,000 | $50 | $3,000,000 | 155,262 (Indirect) | View |
| 2020-11-17 Purchase | 2020-11-19 4:39 pm | Keros Therapeutics Inc. | KROS | Kariv Tomer Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. Director 10% Owner | 60,000 | $50 | $3,000,000 | 155,262 (Indirect) | View |
| 2020-11-17 Purchase | 2020-11-19 4:40 pm | Keros Therapeutics Inc. | KROS | Nussbaum Ran Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. Director 10% Owner | 60,000 | $50 | $3,000,000 | 155,262 (Indirect) | View |
| 2021-02-11 Sale | 2021-02-16 5:47 pm | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 5,300 | $64.91 | $344,017 | 27,991 (Direct) | View |
| 2021-02-11 Sale | 2021-02-16 5:49 pm | Keros Therapeutics Inc. | KROS | Ordonez Claudia Chief Medical Officer | 1,000 | $64.84 | $64,841 | 0 (Direct) | View |
| 2021-02-11 Sale | 2021-02-16 5:50 pm | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 19,029 | $63.53 | $1,208,936 | 450,930 (Indirect) | View |
| 2021-02-16 Sale | 2021-02-18 6:46 pm | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 28,617 | $60.87 | $1,742,043 | 439,634 (Indirect) | View |
| 2021-03-01 Sale | 2021-03-03 8:40 pm | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 23,690 | $61.13 | $1,448,078 | 430,283 (Indirect) | View |
| 2021-03-03 Sale | 2021-03-05 7:44 pm | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 23,959 | $56.45 | $1,352,499 | 420,825 (Indirect) | View |
| 2021-03-11 Sale | 2021-03-15 4:43 pm | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 5,300 | $64.48 | $341,750 | 61,191 (Direct) | View |
| 2021-03-11 Sale | 2021-03-15 4:45 pm | Keros Therapeutics Inc. | KROS | Ordonez Claudia Chief Medical Officer | 1,000 | $64.56 | $64,556 | 0 (Direct) | View |
| 2021-04-01 Sale | 2021-04-05 9:11 pm | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 38,353 | $59.72 | $2,290,536 | 405,685 (Indirect) | View |
| 2021-04-06 Sale | 2021-04-08 4:35 pm | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 9,298 | $58.81 | $546,840 | 402,015 (Indirect) | View |
| 2021-04-12 Sale | 2021-04-14 4:43 pm | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 5,300 | $60 | $318,026 | 71,187 (Direct) | View |
| 2021-04-12 Sale | 2021-04-14 4:46 pm | Keros Therapeutics Inc. | KROS | Ordonez Claudia Chief Medical Officer | 1,000 | $59.93 | $59,926 | 0 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2020-04-07 Option Award | 2020-04-08 9:00 pm | N/A 2030-04-06 | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 241,222 | $0 | 241,222 (Direct) | View |
| 2020-04-07 Option Award | 2020-04-08 9:01 pm | N/A 2030-04-06 | Keros Therapeutics Inc. | KROS | Ordonez Claudia Chief Medical Officer | 18,430 | $0 | 18,430 (Direct) | View |
| 2020-04-07 Option Award | 2020-04-08 9:02 pm | N/A 2030-04-06 | Keros Therapeutics Inc. | KROS | Regnante Keith CFO | 18,430 | $0 | 18,430 (Direct) | View |
| 2020-04-07 Option Award | 2020-04-08 9:02 pm | N/A 2030-04-06 | Keros Therapeutics Inc. | KROS | Regnante Keith CFO | 133,622 | $0 | 133,622 (Direct) | View |
| 2020-04-07 Option Award | 2020-04-08 9:03 pm | N/A 2030-04-06 | Keros Therapeutics Inc. | KROS | Seehra Jasbir CEO | 696,569 | $0 | 696,569 (Direct) | View |
| 2020-04-13 Conversion | 2020-04-13 5:12 pm | N/A N/A | Keros Therapeutics Inc. | KROS | GORDON CARL L Director | 744,612 | $0 | 744,612 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:12 pm | N/A N/A | Keros Therapeutics Inc. | KROS | GORDON CARL L Director | 148,922 | $0 | 148,922 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:12 pm | N/A N/A | Keros Therapeutics Inc. | KROS | GORDON CARL L Director | 744,612 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:12 pm | N/A N/A | Keros Therapeutics Inc. | KROS | GORDON CARL L Director | 148,922 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 1,363,542 | $0 | 1,734,395 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 663,825 | $0 | 844,371 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 737,226 | $0 | 937,735 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 169,307 | $0 | 1,903,702 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 82,425 | $0 | 926,796 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 91,538 | $0 | 1,029,273 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 68,654 | $0 | 68,654 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 163,612 | $0 | 2,067,314 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 88,460 | $0 | 1,015,256 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 79,653 | $0 | 1,108,926 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 36,858 | $0 | 105,512 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 1,363,542 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 663,825 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 737,226 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 169,307 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 82,425 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 91,538 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 68,654 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 163,612 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 88,460 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 79,653 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Kariv Tomer Director 10% Owner | 36,858 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 276,459 | $0 | 414,688 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 184,305 | $0 | 276,458 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 205,962 | $0 | 620,650 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 137,308 | $0 | 413,766 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 67,015 | $0 | 687,665 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 44,676 | $0 | 458,442 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 276,459 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 184,305 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 205,962 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 137,308 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 67,015 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:13 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Knowles Julius Director | 44,676 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:15 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lazarus Alon Director 10% Owner | 1,382,295 | $0 | 1,382,295 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:15 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lazarus Alon Director 10% Owner | 343,270 | $0 | 1,725,565 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:15 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lazarus Alon Director 10% Owner | 167,537 | $0 | 1,893,102 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:15 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lazarus Alon Director 10% Owner | 1,382,295 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:15 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lazarus Alon Director 10% Owner | 343,270 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:15 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lazarus Alon Director 10% Owner | 167,537 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 1,363,542 | $0 | 1,734,395 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 663,825 | $0 | 844,371 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 737,226 | $0 | 937,735 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 169,307 | $0 | 1,903,702 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 82,425 | $0 | 926,796 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 91,538 | $0 | 1,029,273 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 68,654 | $0 | 68,654 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 163,612 | $0 | 2,067,314 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 88,460 | $0 | 1,015,256 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 79,653 | $0 | 1,108,926 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 36,858 | $0 | 105,512 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 1,363,542 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 663,825 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 737,226 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 169,307 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 82,425 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 91,538 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 68,654 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 163,612 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 88,460 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 79,653 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:16 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Nussbaum Ran Director 10% Owner | 36,858 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:17 pm | N/A N/A | Keros Therapeutics Inc. | KROS | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC Director | 744,612 | $0 | 744,612 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:17 pm | N/A N/A | Keros Therapeutics Inc. | KROS | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC Director | 148,922 | $0 | 148,922 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:17 pm | N/A N/A | Keros Therapeutics Inc. | KROS | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC Director | 744,612 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:17 pm | N/A N/A | Keros Therapeutics Inc. | KROS | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC Director | 148,922 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 1,363,542 | $0 | 1,734,395 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 663,825 | $0 | 844,371 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 737,226 | $0 | 937,735 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 169,307 | $0 | 1,903,702 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 82,425 | $0 | 926,796 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 91,538 | $0 | 1,029,273 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 68,654 | $0 | 68,654 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 163,612 | $0 | 2,067,314 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 88,460 | $0 | 1,015,256 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 79,653 | $0 | 1,108,926 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 36,858 | $0 | 105,512 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 1,363,542 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 663,825 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 737,226 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 169,307 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 82,425 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 91,538 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 68,654 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 163,612 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 88,460 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 79,653 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:18 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Pontifax Management 4 G.P. (2015) Ltd. Pontifax (Israel) IV L.P. Pontifax (Cayman) IV L.P. Pontifax (China) IV L.P. Pontifax Late Stage Fund L.P. Pontifax Late Stage GP Ltd. 10% Owner | 36,858 | $0 | 0 (Indirect) | View |
| 2020-04-13 Conversion | 2020-04-13 5:19 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Seehra Jasbir CEO | 11,169 | $0 | 223,856 (Direct) | View |
| 2020-04-13 Conversion | 2020-04-13 5:19 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Seehra Jasbir CEO | 11,169 | $0 | 0 (Direct) | View |
| 2020-04-13 Conversion | 2020-04-13 5:29 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Arkin Bio Ventures Limited Partnership Arkin Bio Venture Partners Ltd. Arkin Moshe 10% Owner | 1,382,295 | $0 | 1,382,295 (Direct) | View |
| 2020-04-13 Conversion | 2020-04-13 5:29 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Arkin Bio Ventures Limited Partnership Arkin Bio Venture Partners Ltd. Arkin Moshe 10% Owner | 343,270 | $0 | 1,725,565 (Direct) | View |
| 2020-04-13 Conversion | 2020-04-13 5:29 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Arkin Bio Ventures Limited Partnership Arkin Bio Venture Partners Ltd. Arkin Moshe 10% Owner | 167,537 | $0 | 1,893,102 (Direct) | View |
| 2020-04-13 Conversion | 2020-04-13 5:29 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Arkin Bio Ventures Limited Partnership Arkin Bio Venture Partners Ltd. Arkin Moshe 10% Owner | 1,382,295 | $0 | 0 (Direct) | View |
| 2020-04-13 Conversion | 2020-04-13 5:29 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Arkin Bio Ventures Limited Partnership Arkin Bio Venture Partners Ltd. Arkin Moshe 10% Owner | 343,270 | $0 | 0 (Direct) | View |
| 2020-04-13 Conversion | 2020-04-13 5:29 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Arkin Bio Ventures Limited Partnership Arkin Bio Venture Partners Ltd. Arkin Moshe 10% Owner | 167,537 | $0 | 0 (Direct) | View |
| 2020-05-29 Option Award | 2020-05-29 5:19 pm | N/A 2030-05-29 | Keros Therapeutics Inc. | KROS | Farzan Nima Director | 8,500 | $0 | 8,500 (Direct) | View |
| 2020-12-17 Option Award | 2020-12-21 4:43 pm | N/A 2030-12-16 | Keros Therapeutics Inc. | KROS | GRAY MARY ANN Director | 16,587 | $0 | 16,587 (Direct) | View |
| 2021-01-10 Option Award | 2021-01-12 5:20 pm | N/A 2031-01-09 | Keros Therapeutics Inc. | KROS | Seehra Jasbir CEO | 127,200 | $0 | 127,200 (Direct) | View |
| 2021-01-10 Option Award | 2021-01-12 5:21 pm | N/A 2031-01-09 | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 42,250 | $0 | 42,250 (Direct) | View |
| 2021-01-10 Option Award | 2021-01-12 5:23 pm | N/A 2031-01-09 | Keros Therapeutics Inc. | KROS | Ordonez Claudia Chief Medical Officer | 42,250 | $0 | 42,250 (Direct) | View |
| 2021-01-10 Option Award | 2021-01-12 5:25 pm | N/A 2031-01-09 | Keros Therapeutics Inc. | KROS | Regnante Keith CFO | 49,150 | $0 | 49,150 (Direct) | View |
| 2021-02-11 Exercise | 2021-02-16 5:47 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 5,300 | $0.3 | 33,291 (Direct) | View |
| 2021-02-11 Exercise | 2021-02-16 5:47 pm | N/A 2028-03-25 | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 5,300 | $0 | 145,605 (Direct) | View |
| 2021-02-11 Exercise | 2021-02-16 5:49 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Ordonez Claudia Chief Medical Officer | 1,000 | $0.48 | 1,000 (Direct) | View |
| 2021-02-11 Exercise | 2021-02-16 5:49 pm | N/A 2029-09-18 | Keros Therapeutics Inc. | KROS | Ordonez Claudia Chief Medical Officer | 1,000 | $0 | 102,211 (Direct) | View |
| 2021-02-26 Exercise | 2021-03-01 4:54 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 33,200 | $0.11 | 61,191 (Direct) | View |
| 2021-02-26 Exercise | 2021-03-01 4:54 pm | N/A 2027-02-05 | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 33,200 | $0 | 9,996 (Direct) | View |
| 2021-03-11 Exercise | 2021-03-15 4:43 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 5,300 | $0.3 | 66,491 (Direct) | View |
| 2021-03-11 Exercise | 2021-03-15 4:43 pm | N/A 2028-03-25 | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 5,300 | $0 | 140,305 (Direct) | View |
| 2021-03-11 Exercise | 2021-03-15 4:45 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Ordonez Claudia Chief Medical Officer | 1,000 | $0.48 | 1,000 (Direct) | View |
| 2021-03-11 Exercise | 2021-03-15 4:45 pm | N/A 2029-09-18 | Keros Therapeutics Inc. | KROS | Ordonez Claudia Chief Medical Officer | 1,000 | $0 | 101,211 (Direct) | View |
| 2021-04-01 Exercise | 2021-04-02 4:32 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 9,996 | $0.11 | 71,187 (Direct) | View |
| 2021-04-01 Exercise | 2021-04-02 4:32 pm | N/A 2027-02-05 | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 9,996 | $0 | 0 (Direct) | View |
| 2021-04-12 Exercise | 2021-04-14 4:43 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 5,300 | $0.3 | 76,487 (Direct) | View |
| 2021-04-12 Exercise | 2021-04-14 4:43 pm | N/A 2028-03-25 | Keros Therapeutics Inc. | KROS | Lachey Jennifer Chief Scientific Officer | 5,300 | $0 | 135,005 (Direct) | View |
| 2021-04-12 Exercise | 2021-04-14 4:46 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Ordonez Claudia Chief Medical Officer | 1,000 | $0.48 | 1,000 (Direct) | View |
| 2021-04-12 Exercise | 2021-04-14 4:46 pm | N/A 2029-09-18 | Keros Therapeutics Inc. | KROS | Ordonez Claudia Chief Medical Officer | 1,000 | $0 | 100,211 (Direct) | View |